|
PercSys OverviewPercSys is a young medical device company focused on the design, development, and commercialization of novel interventional devices for the minimally invasive treatment of urologic disorders. Our goal is to develop devices for use in hospital, office, and clinic environments that make urologic and endoscopic procedures easier to perform, more comfortable for patients, and more effective therapeutically. In this way, we seek to transform the practice of urology to benefit physicians, patients, and payers. Our product development efforts are aimed at the large and growing urology device market. Estimated at $4.8 billion worldwide and $2.5 billion in the U.S., this market is increasing at an annual rate of approximately 15 percent, driven by the demographics of an aging population. In June 2007, we introduced our first product, the PercSys Accordion® Stone Management Device, an advanced microcatheter system for aiding in the treatment of kidney stones in the ureter. By offering the utility of multiple endoscopic stone management tools in a single device, the Accordion device is designed to simplify and shorten stone fragmentation and removal procedures. We plan to introduce additional products based on the Accordion platform in the coming year. Founded in 2003, PercSys is led by an experienced management team with proven expertise in the development and commercialization of medical devices for a broad range of clinical applications. Since our establishment, we have received equity investments from Compass Technology Partners, Montreux Equity Partners, and Shea Ventures, as well as private investors. |